BRIEF—Terumo Pharmaceutical Solutions expands CDMO services

Terumo Corp’s Terumo Pharmaceutical Solutions (TPS) unit intends to expand its contract development and manufacturing services for parenteral drugs to global customers.

Terumo is a well-established integrated CDMO in Japan offering end-to-end services for more than 20 years, supporting customers with pre-filled syringe (PFS) design, molding, drug preparation, filling, assembly, and final packaging for challenging biotech drugs and small molecules.

The company, which has three CDMO sites in Japan, stated that the expansion would involve engaging on projects that cover the early development stage to large scale commercial production for global pharmaceutical customers including assembly of PFS with devices like autoinjectors, needle safety devices, and supporting customers for regulatory submissions globally

Terumo is investing to expand the CDMO production facilities for pre-filled syringes at its wholly owned subsidiary Terumo Yamaguchi corporation (Yamaguchi City).

The total investment, including peripheral equipment, will be 15 billion yen ($102 million).

As a result, Terumo Yamaguchi D&D's production capacity will increase by 3.5 times compared to when the plant started operation in 2016.